The timely establishment of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) network (May 28, p 2197) 1 of research funding organisations in 2013 is an exciting development and fits neatly with the research and development (R&D) Blueprint Initiative of WHO.
In May, 2015, the 68th World Health Assembly "welcomed the development of a blueprint, in consultation with Member States and relevant stakeholders, for accelerating research and development in epidemics or health emergency situations where there are no, or insufficient, preventive, and curative solutions, taking into account other relevant work streams within WHO". 2 The R&D Blueprint aims to reduce the time between the declaration of an international public health emergency and the availability of effective tests, vaccines, antivirals, and other treatments that can save lives and avert a public health crisis.
WHO expert teams, an international scientifi c advisory group, and several partners engaged via global forums have been collaborating to articulate this novel R&D model. Several activities have been developed, experiences from the R&D efforts during the west African Ebola outbreak have provided a starting point, and the Zika virus outbreak in the Americas has served as an important testing ground.
The WHO R&D Blueprint is both a convening mechanism for public health officials, scientists, and product developers, and an instrument to articulate technical guidance for R&D preparedness and response, especially in the area of coordination (ie, addressing priorities and avoiding unnecessary duplication), that can be eff ectively implemented through norm setting, appropriate incentives, and other measures.
WHO collaborates and works in partnership with several initiatives enhancing high-impact research collaboration with our colleagues across Europe. DN The European Union (EU) has supported the development of research networks across the continent through the Erasmus and Marie Curie exchange programmes, Horizon 2020 funding, and harmonisation of regulation. We accept that diverse and complex arguments exist for modifying the UK's political and financial relationship with the EU. However, there is considerable uncertainty regarding the full impact of Brexit on pan-European medical research. We are concerned that future UK access to EU initiatives and funding sources might be limited, and that the referendum result risks sending a negative message to our European collaborators.
Trainees belong to a younger generation that overwhelmingly voted to remain in the EU, a generation that has embraced the globalisation of medical research and the attendant opportunities for advancing medical science and patient care. 5 Science transcends national boundaries, and the very best research has always relied on the free exchange of information and ideas. For this reason, it is now more important than ever to ensure that incentives for international collaboration-such as research funding, training fellowships, and reciprocal exchanges-between the UK and EU continue to advance scientifi c and medical research for the benefi t of patients a cross borders.
As a group of early-career researchers and trainees, we are the future of surgical research in the UK. We remain as committed as ever to leading and
The need for global R&D coordination for infectious diseases with epidemic potential
The relentless increase of public health crises caused by emergent, often life-threatening infectious diseases-eg, Nipah virus infection, severe acute respiratory syndrome, avian influenza, Middle East respiratory syndrome, Ebola virus disease, chikungunya, Zika virus infection, and now yellow feverneeds no introduction. In an increasingly globalised world, a coherent global response is needed, not only in the immediate care of patients and countermeasures to transmission but also in the prompt initiation of research eff orts.
A call for transparency in the evaluation of global maternal health projects
In view of frequent discussions surrounding measurable eff ectiveness of maternal health programmes and learning from failure-as highlighted at both the Women Deliver 2016, and Global Maternal Health 2015 conferences-we wish to draw attention to how practices in global maternal health create perverse incentives to prevent learning that could potentially improve interventional approaches. A key challenge in global maternal health currently is the incongruity between successes-invariably reported at discrete programme level-and the collective lack of progress in global maternal mortality. Evaluations of numerous projects consistently suggest a preponderance of successful interventions, 1 yet collectively 69 of 75 high-burden countries failed to achieve their Millenium Development Goal-5 targets. 2, 3 As project evaluators, we have encountered concerning instances in which unwelcome findings were selectively unreported, or led to contractual terminations. Similar experiences have been echoed by colleagues in diverse geographical contexts. This necessitates consideration of three points: fi rst we must consider how to protect the independence of evaluators and prevent the silencing of important evaluation insights. The scientific community has a duty of candour. We suggest an international evaluation registry, along the lines of the International Standard Randomised Controlled Trial Number 4 be established to increase transparency and reduce selective reporting. Second, conflicts of interest prevent funders and implementing agencies from sharing negative, yet important programmatic evaluation results. There is a need to disentangle the associations between project outcomes and individual or institutional credibility, and create safeguards for reporting of negative fi ndings. Third, we should assess whether the current evidence base produced by project evaluations can be trusted, given this positive evaluation bias. It seems likely that the more problematic a project, the less likely we are to learn of its shortcomings. As a result, we are less likely to make substantive changes to our practice.
Such goals will require a systematic and thorough exploration of the current practice of global maternal health evaluation, a strong focus on scientific independence, and for all stakeholders to take responsibility for facilitating the reporting of challenges and failures.
We declare no competing interests. that are being implemented by international stakeholders and that complement the efforts of the R&D Blueprint. We welcome GloPID-R's partnership and commitment to improve the sharing of information among funders, align decision making, and allow for an expedited and coordinated approach among many major global funding agencies. However, most individual funding agencies are likely to make decisions on a case-by-case basis in line with their mandates and mission.
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To fulfil its mandate, WHO has a core responsibility in the area of research and coordination of research. WHO will use its convening capacity to fulfil this responsibility. Although WHO is not a funding agency nor in general a major implementer of research activities, it has a global mandate to set evidence-based priorities and standards for research, ensuring that all voices are heard and avoiding conflicts of interests. Success of the R&D Blueprint will certainly depend on the concerted efforts of all stakeholders.
